Procaps S.A. has completed a private placement of senior notes
Procaps S.A. has raised funds to refinance existing debt with new institutional investors.
Procaps is a leading integrated international healthcare and pharmaceutical company that develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps has a product reach in 50 markets and has strategically positioned itself to achieve its M&A initiative and expand new product categories in the B2B and B2C segments.
Oaklins’ team in Chile acted as the sole financial advisor to Procaps S.A. in the private placement of senior unsecured fixed-rate notes for an aggregate principal amount of US$115 million.


Talk to the deal team


Related deals
SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.
Learn moreAgar Scientific has been acquired by Calibre Scientific
Agar Scientific Ltd. (Agar) has been sold to Molecular Dimensions Limited, a subsidiary of Calibre Scientific, Inc., a US-based life sciences company, owned by international private investment firm StoneCalibre.
Learn moreCooper Consumer Health has sold Stardea to EA Pharma
Cooper Consumer Health has sold Stardea to EA Pharma.
Learn more